SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also con
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chi
FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.65 per share a year ago.
FibroGen Inc. FGEN saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in pancreatic cancer patients.
FibroGen Inc. FGEN saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in pancreatic cancer patients.
FibroGen (NASDAQ: FGEN ) layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. FibroGen says that it is going into a cost-sa

Why Is FibroGen (FGEN) Stock Down 44% Today?

08:31am, Wednesday, 31'st Jul 2024
FibroGen (NASDAQ: FGEN ) stock is falling hard on Wednesday after the biopharmaceutical company reported results from failed clinical trials. The first failed clinical trial covers the treatment of m
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also condu
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate in the following investor conferences:
FibroGen, Inc. (NASDAQ:FGEN ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A and IR Thane Wettig - CEO Deyaa Adib - CMO Juan Graham - C
SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2024 and provided an update on the company's recent developments.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE